Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global BrandsBusiness Wire • 10/28/21
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid TumorsBusiness Wire • 10/27/21
Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900MGeekWire • 10/14/21
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into MassachusettsBusiness Wire • 10/13/21
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without ResistanceBusiness Wire • 10/07/21
‘Human Error' Caused Contamination Of Moderna Vaccines In Japan, Distributor Takeda SaysForbes • 10/01/21
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR PharmaceuticalsBusiness Wire • 09/30/21
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income CountriesBusiness Wire • 09/22/21
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in JapanBusiness Wire • 09/21/21
